Amphotericin B lipid complex (ABLC): New formulation of a new classic antifungal;Anfotericina B complejo lipídico (ABLC): Nueva formulación de un antifúngico clásico

Revista Iberoamericana de Micologia

Volumn 13, Issue SUPPL. 2, 1996, Pages

  Madrenys I Brunet, N ^a   Torres Rodriguez J M ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

Amphotericin B; Lipid complex; Mycosis; Pharmacokinetic

Indexed keywords

EID: 2742615978     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Fox JL Fungal infection rates are increasing. ASM News 1993, 59 515-518
2. Bodey G, Bueltmann B, Duguid W et al. Fungal infections in cancer patients an international autopsy survey Eur J Clin Microbiol Infect Dis 1992, 11:99-109
3. Wade JC. Epidemiology of Candida infections. En. Bodey GP Candidiasis Pathogenesis, Diagnosis and Treatment. New York. Raven Press 1993 85-107.
4. Palacios J, Serrano R. Proton permeability induced by polyene antibiotics A plausible mechanism for their inhibition of maltose fermentation in yeast FEBS Letters 1978; 91 198-201
5. Szoka FC, Tang M. Amphotericin B formulated in liposomes and lipid bases systems A review J Liposome Res 1993, 3: 363-375
6. Bolard J, Joly V, Yeni P Mechanism of action of amphotericin B at the cellular level its modulation by delivery systems J Liposome Res 1993; 3: 409-428
7. New RPC, Chance ML, Heath J Anti leishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother 1981, 8 371
8. Taylos RL, Williams DM, Graven PC, Graybill JR, Drutz DJ, Magee WE Amphotericin B in liposomes: a novel therapy for histoplasmosis Ann Rev Resp Dis 1982, 125 610
9. Graybill JR, Craven PC PC, Taylor RL, Williams DM, Magee WE Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis 1982, 145: 748
10. López-Berestein G, Metha R, Hopfer R, Mehta K, Hersh EM, Juliano R. effects of sterols on the therapeutic efficacy of liposomal-associated amphotericin B J Infect Dis 1983, 1 37
11. López-Berestein G, Mehta R, Hopfer RL, Mills K, Kasi L, Mehta K, Fainstein V, Luna W, Hersh EM, Juliano RL Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome encapsulated amphotericin B J Infec Dis 1983, 147: 939
12. López-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EM, Reuben J, Juliano RL, Bodey GP Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer, a preliminar study. J Infect Dis 1985, 151 704
13. López-Berestein G, Bodey GP, Frankel LS, Mehta K Treatment of hepatosplenic candidiasis with liposomal amphotericin B J Clin Oncol 1987, 5 310
14. Weber RS, López-Berestein G. Treatment of invasive Aspergillus sinusitis with liposomal amphotericin B. Laryngoscope 1987; 97 937
15. Janoff AS, Boni LT, Popescu MC et al Unusual lipid structures selectivrly reduce the toxicity of amphotericin B Proceed National Acade Scien 1988, 85 6122-61216
16. Janoff AS, Perkins WR, Saletan SL, Swenson CE Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxicities J Liposome Res 1993, 3 451-471
17. Banghan AD Liposomes, realising their promise Hospital Practice 1992, 27 51-62
18. Clark JM, Whitney RR, Olsen SJ et al Amphotericin B Lipid Complex therapy of experimental fungsl infetions in mice Antim Ag Chem 1991; 35: 615-621
19. Olsen SJ, Swerdel MR, Blue B et al Tissue distribution of amphotericin B lipid complex in laboratory animals. J Phar Pharm 1991, 43 831-835
20. Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, Bonner DP Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991, 35: 615-621
21. Kline S Larsen TA, Fieber L, Fishbach R, Greenwood M, Harris R, Kline MW, Tennican PO, Janoff EN. Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Clin Inf Dis 1995, 21; 1154-1158
22. Graybill JR, Sharkey PK, Vincent D, Johnson E, Havard PF et al Amphotericin B lipid complex in treatment of cryptococcal meningitis in patients with AIDS. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago 1991; Abst 289: 147
23. Sharkey PK, Lipke R, Ronteria A, Galgiani J, Catanzaro A et al Amphotericin B lipid complex in treatment of coccidioidomycosis. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago 1991; Abstract 742.222
24. Kline S, Larsen TA, Fieber L, Fishbach R, Greenwood M Harris R, Kline MW, Tennican PO, Janoff EN Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Clin Infec Dis 1995, 21: 1154-1158
25. Bow EJ Safety and efficacy of Amphotericin B lipid complex (ABLC) in systemic candidiasis. 8th International Symposium on Infections in the Immunocompromised Host.Davos. 1994
26. Anaissie E Amphotericin B Lipid Complex (Albelcet) versus amphotericin B for the treatment of invasive candidiasis: A prospective, randomised, multicentre trial Abstr Second meeting of the European Haematology Association. Paris 1996
27. Herrmann RP. Hepatosplenic candidiasis treated with amphotericin B lipid complex. J Develop Clinic Pract 1996, 4.3-4
28. Harris RE, Sambiano J Disseminated candidiasis with renal impairment J Develop Clinic Pract 1996; 4:9-10
29. Walsh TJ, Hiemenz JW, Seibel N, Anaissie EJ Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis 34th Interscience Conference on Antimicrobial Agents and Chemotherapy Orlando 1994, Abstract M69.
30. Wingard JR. Efficacy and Safety of Amphotericin B Lipid Complex (ABLC, Abelcet) in Bone Marrow Transplant (BMT) pateints with Life-Threatening Systemic Mycoses. Second Meeting of the European Haematology Association Paris 1996
31. Wingard J Management of aspergillosis: Treatment strategies in BMT. Second Meeting of the EHA Paris 1996
32. Rousselot P, Jablon L, Chaibi P, Dombret H, Degos L Clinical efficacy of amphotericin B lipid complex (ABLC) in malignant Aspergillus rhinosinusitis Second meeting of the European Haemototogy Association Paris, 1996
33. Anaissie EJ, Ramphal R. Efficacy and safety of amphotericin B lipid complex (ABLC) in the treatment of patients with life-threatening fusariosis. 34th Intersci Conf Antimicrob Agents Chemother, Orlando, 1994; Abst M87
34. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RS, et al Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS Clin Inf Dis 1996, 22: 315-321
35. Castagnola E, Micalizzi C, Giacchino R, Lavagetto A, Molinari AC, Rossi GA, Jasonni V, Mori PG. Survival of a patient with aplastic anaemia complicated with pulmonary zygomycosis treated by high-dose amphotericin B lipid complex. J Develop Clinic Pract 1996; 4 5-6
36. Quinones R, Dinndorf P. Amphotericin B lipid complex in the treatment of invasive aspergillosis following bone marrow transplantation. J Develop Clinc Pract 1996, 4 7-8
37. Herbreht R, timmel MC, Tabone MD, Le Bouar V, Guillemain R, Pailler A, Suc A, Eyer D, Leverger G, Schaison G Amphotericin B lipid complex (ABLC) treatment in children with invasive fungal infections Second Meeting of the European Haematology Association. Paris 1996
38. Lister J Amphotericin B lipid complex (Abelcet) in the treatment of invasive mycoses the North American experience. Eur J Haematol 1996; 56 (suppl 57): 18-23